Lipid Metabolism In Patients Research Articles

Evaluation of the efficacy of Baduanjin in improving glucose and lipid metabolism in patients with prediabetes: a meta-analysis of randomized controlled trials

Objective: The study systematically evaluated the effects of Baduanjin with different time, frequency and cycle on glucose and lipid metabolism in patients with prediabetes of different ages. Methods: Randomized controlled trials (RCTs) on the effect of Baduanjin exercise on PDM patients were comprehensively searched in PubMed, Embase, CNKI and other databases. The retrieval time was from the establishment of the database to September 2022. Results: a total of 13 items of RCT were included in this study, including 415 patients in the trial group and 405 patients in the control group. The results of Meta-analysis showed that FPG (MD-0.45, 95%CI:-0.60, P<0.0l), P < 0.05.The results showed that Baduanjin was superior to the control group in fasting blood glucose in patients with prediabetes, and TG (MD=-0.29,95%CI:-0.52 Baduanjin was better than the control group in improving triglyceride (TG). HDL-C (MD=0.06,95%CI:0.02~0.11,P < 0.01), P < 0.05.Results showed that the intervention group of Baduanjin was superior to the control group in improving high density lipoprotein cholesterol (HDL-C) in patients with prediabetes. LDL-C (MD=-0.27,95% CI:-0.44~-0.10,P=0.002), P < 0.05.The results showed that the intervention group of Baduanjin was superior to the control group in improving low density lipoprotein cholesterol (LDL-C) in prediabetic patients. The results of TC (MD=--0.36,95%CI:-0.60~-0.12,P=0.004 < 0.05) showed that the intervention group was superior to the control group in improving serum total cholesterol (TC) in patients with prediabetes. The results of subgroup analysis showed that when the age of the patients<60 years old, the intervention time ≥ 60 minutes, the intervention period ≥ 6 months and the intervention frequency ≥ 5 days, the Baduanjin was superior to the control group in improving the indexes of prediabetes. Conclusion: Baduanjin can further improve the level of glucose and lipid metabolism in patients with prediabetes, especially in FPG, TC, HDL-C and LDL-C.

Vitamin D and cardiometabolic risk factors for the development and progression of type 2 diabetes and its complications

Type 2 diabetes (T2D) and vitamin D deficiency are so common in the population that they are referred to as pandemics, which justifies the use of vitamin D to correct its deficiency. Objective. To study the association between vitamin D status in patients with T2D and cardiometabolic risk factors for the development of T2D and its complications, as well as to analyze the dose-time dependence of the effectiveness of vitamin D deficiency correction according to recent data. Results. The prevalence of vitamin D deficiency among patients with T2D is quite high and is even more common in patients with complicated T2D. There was a significant negative correlation between serum 25(OH)D concentrations and the levels of fasting plasma glucose, HbA1c, cholesterol, LDL cholesterol, and body mass index (BMI), while there was a positive correlation between the levels of 25(OH)D and HDL cholesterol. A consensus was reached on the need to optimize vitamin D status in T2D patients. Different doses and regimens of vitamin D supplementation are used to correct vitamin D deficiency. Important factors in the effectiveness of vitamin D administration are the patients’ baseline vitamin D status, dosage and duration of vitamin D3 intake. The effect of vitamin D3 on serum 25(OH)D concentrations was shown to be more pronounced in individuals with initial vitamin D deficiency. To correct vitamin D deficiency, the duration of administration should be 3 to 6 months, using doses that are not less than the recommended daily intake. High doses of vitamin D (more than 2000 IU/day) were more effective in correcting serum 25(OH)D levels and improving glycemic control and lipid metabolism in patients with T2D and vitamin D deficiency. Conclusions. To eliminate the lack of vitamin D, its daily long-term administration at a dose of 800–1000 IU is advisable. Optimization of vitamin D supply should be considered as a part of diet therapy for T2D, contributing to the mitigation of clinical manifestations of the disease and its associated complications. Key words: type 2 diabetes, insulin resistance, vitamin D, doses, efficacy

Assessment of the Nature of Dyslipoproteinemias and Correlations of Indicators of General Reactivity and Lipid Metabolism in Patients with Chronic Nonspecific Inflammation of the Reproductive System

Metabolic disorders can occur at all levels of biological organization - from molecular and cellular to the level of the organism as a whole. These changes may result from disruptions in hormonal mechanisms, actions of pathogenic factors, or infections. Primary metabolic disorders are the basis of many diseases, such as diabetes, obesity, and atherosclerosis, while secondary disorders accompany most pathological processes. Disruption of lipid metabolism leads to changes in their functions and the development of pathological processes, such as dyslipoproteinemia, and also contributes to the development of atherosclerosis. Various intracellular infectious agents play a significant role in the development of dyslipoproteinemias and atherosclerosis, for example, chlamydia can alter the lipid metabolism in macrophages under the influence of low-density lipoproteins, leading to the formation of 'foam-like' cells. This, in turn, contributes to the development of atheromatous plaques-a favorable environment for chlamydia, where it can survive for an extended period and trigger immunopathological mechanisms.

Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach.

The types and functions of lipids involved in glioblastoma (GB) are not well known. Lipidomics is a new field that examines cellular lipids on a large scale and novel aplication of lipidomics in the biomedical sciences have emerged. This study aimed to investigate the potential of blood lipids for use as biomarkers for the diagnosis of GB via untargated lipidomic approach. Gaining a deeper understanding of lipid metabolism in patients with GB can contribute to the early diagnosis with GB patiens and also development of novel and better therapeutic options. This study was performed using blood samples collected from 14 patients (eight females and six males) and 14 controls (eight females and six males). Lipids were extracted from blood samples and quantified using phosphorus assay. Lipid profiles of between patients with GB and controls were compared via an untargeted lipidomics approach using 6530 Accurate-Mass Q-TOF LC/MS mass spectrometer. According to the results obtained using the untargeted lipidomics approach, differentially regulated lipid species, including fatty acid (FA), glycerolipid (GL), glycerophospholipid (PG), saccharolipid (SL), sphingolipid (SP), and sterol lipid (ST) were identified between in patients with GB and controls. Differentially regulated lipids were identified in patients with GB, and these lipid species were predicted as potential biomarkers for diagnosis of GB.

Clinical observation on acupuncture for 80 patients with abdominal obesity in Germany: based on the theory of unblocking and regulating the Belt Vessel

ObjectiveTo observe the efficacy of unblocking and regulating the Belt Vessel acupuncture method for patients with abdominal obesity in Germany and its influence on the body fat parameters and glycolipids metabolism.MethodsA total of 82 cases of abdominal obesity in Germany were selected. There were two dropout cases in the treatment process. All of the patients received acupuncture at Daimai (GB26), Daheng (SP15), Tianshu (ST25), Zhongwan (CV12), Shuidao (ST28), Waiguan (TE5), and Zulinqi (GB41). The patients received acupuncture therapy once every 2–3 d, 3 times a week. The treatment duration lasted 4 weeks. Before and after treatment, the body mass (BM), waist circumference (WC), abdominal circumference (AC), hip circumference (HC), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and fasting blood glucose (GLU) were measured respectively, and the body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and body fat rate (BFR) were calculated.ResultsAfter treatment, the total effective rate was 72.5%; the levels of BM, WC, AC, HC, BMI, WHR, WHtR, BFR, TC, LDL-C, and GLU declined significantly compared with those before treatment (P<0.01), while the TG and HDL-C slightly declined, but the differences were statistically insignificant (P>0.05).ConclusionThe unblocking and regulating the Belt Vessel acupuncture method can significantly reduce body fat parameters such as BM, AC, and BFR, and correct the disorders of glucose and lipid metabolism in patients with abdominal obesity in Germany.

Coumarin-4-yl‐1,2,3‐triazol‐4-yl-methyl-thiazolidine-2,4-diones: Synthesis, glucose uptake activity and cytotoxic evaluation

Thiazolidinedione (TZD) based medications have demonstrated to enhance the insulin sensitivity control, hyperglycemia, and lipid metabolism in patients with type 2 diabetes. Hence, in this study, a new series of novel coumarin-4-yl-1,2,3-triazol-4-yl-methyl-thiazolidine-2,4-diones (TZD1-TZD18) were synthesized via copper (I)-catalyzed azide-alkyne cycloaddition “Click Chemistry”. The synthesized compounds were evaluated for their glucose uptake assay and in vitro cytotoxicity against HEK-293 (human embryonic kidney) cells which were compared with the standard drug Pioglitazone. Further, molecular docking analysis of these compounds was carried out to explain the in vitro results with PPARγ (PDB ID: 3CS8) and to better understand the bonding interactions with the target protein. The outcomes of in vitro assessment, molecular docking, and pharmacokinetics of the title compounds were revealed to be highly correlated. Interestingly, the compounds TZD4, TZD10, TZD14 and TZD16 were most efficient in lowering the blood glucose level compared with standard drug.

Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion

Venous and arterial retinal vascular occlusions are age-related disorders, generally associated with classical cardiovascular risk factors, rather than an isolated ocular disease. As affected patients often also have an increased general risk for other vascular diseases, such as ischemic stroke, an interdisciplinary clarification of cardiovascular risk factors and systemic comorbidities is essential for all patients. Extended hemostaseological investigations may be recommended in those patients who do not match the typical risk profile. Patients at a young age by the time of manifestation, without conventional risk factors as well as patients with an increased risk of developing antiphospholipid syndrome may require a selective clinical investigation including testing for thrombophilic risk factors. Recent studies have clearly demonstrated an association between coagulation and lipid metabolism disorders and the development of both retinal vein and artery occlusions in specific subgroups of patients. Therapeutic approaches to treat retinal vascular occlusions or reduce the long-term risk of recurrences with anticoagulant or antiplatelet drugs have not gained widespread acceptance. However, intravenous thrombolysis may be avaluable treatment option for central retinal artery occlusions within a short time to treatment therapeutic window. For defined disorders of the coagulation system, the administration of antithrombotic drugs to reduce the general vascular risk can be a reasonable approach. This article provides an overview of cardiovascular risk factors, the general vascular risk and the current state of knowledge on ophthalmologically relevant disorders of coagulation and lipid metabolism in patients with venous and arterial retinal vascular occlusions.

Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis.

Polycystic ovary syndrome (PCOS) is a multi-factorial heterogeneous syndrome that has both adverse reproductive and metabolic implications for affected women and its management is a challenging clinical problem. Curcumin, as a phenolic compound with potent anti-inflammatory and antioxidant properties exerting positive effects on the lipid profile and insulin resistance, appears to be a valuable treatment regimen for patients with PCOS. This study aimed to evaluate the efficacy and safety of curcumin in the treatment of PCOS. Chinese databases (Chinese National Knowledge Infrastructure, China Biology Medicine Databases, VIP database, Wanfang Database, and Chinese Clinical Trial Registry) and English databases (PubMed, Web of Science, Embase, Cochrane Library, Scopus and Clinical trials) were thoroughly investigated through screening randomized controlled trials on curcumin in PCOS published from the date of inception to May 2022. Standardized data search and abstraction were conducted following the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. Quantitative and qualitative analyses were performed. Heterogeneity was assessed using I2 statistics. A total of 447 patients from seven randomized controlled trials were included in the meta-analysis. Results showed that the ingestion of curcumin decreased body mass index (WMD -0.267, 95% CI -0.450 to -0.084, P = 0.004, I2 = 0.0%), fasting plasma glucose (WMD -3.618, 95% CI -5.165 to -2.071, P < 0.001, I2 = 20.4%), insulin (WMD -1.834, 95% CI -2.701 to -0.968, P < 0.001, I2 = 8.4%), homeostatic model assessment for insulin resistance (WMD -0.565, 95% CI -0.779 to -0.351, P < 0.001, I2 = 0.0%), total cholesterol (WMD -15.591, 95% CI -27.908 to -3.273, P = 0.013, I2 = 68.9%), C-reactive protein (WMD -0.785, 95% CI -1.553 to -0.017, P = 0.045, I2 = 23.9%), and increased the quantitative insulin sensitivity check index (WMD 0.011, 95% CI 0.005 to 0.017, P = 0.001, I2= 39.6%). As for safety, the treatment group did not cause significant adverse reactions than that in the control group. In light of presented findings, curcumin has beneficial effects on serum markers of inflammation, weight loss and glucose and lipid metabolism in patients with PCOS. The incidence of adverse reactions does not increase with the application of curcumin. However, a larger, more definitive study is needed to further investigate these results. https://www.crd.york.ac.uk/prospero/, identifier CRD42022332394.

Correlation study on serum miR-222-3p and glucose and lipid metabolism in patients with polycystic ovary syndrome

ObjectivemicroRNAs (miRNAs) play pivotal roles in polycystic ovary syndrome (PCOS), an endocrine and metabolic disorder that commonly occurs in women of childbearing age. This paper aimed to measure miR-222-3p expression in sera of PCOS patients and to explore its clinical value on PCOS diagnosis and prediction of diabetic and cardiovascular complications.MethodsTotally 111 PCOS patients and 94 healthy people were recruited and assigned to the overweight (ow) group and non-overweight (non-ow) group, followed by determination of serum miR-222-3p expression. The diagnostic efficiency of miR-222-3p on PCOS ow and non-ow patients was analyzed. Correlations between miR-222-3p and glycolipid metabolic indicators and diabetic and cardiovascular complications in PCOS were analyzed. The downstream target of miR-222-3p was predicted and their binding relationship was verified. The correlation between PGC-1α and miR-222-3p was analyzed.ResultsmiR-222-3p was highly-expressed in PCOS patients (p < 0.001), in especially PCOS ow patients. The area under the curve (AUC) of miR-222-3p diagnosing PCOS non-ow patients was 0.9474 and cut-off value was 1.290 (89.06% sensitivity, 98.11% specificity), indicating that non-ow people with serum miR-222-3p > 1.290 could basically be diagnosed with PCOS. AUC of miR-222-3p diagnosing PCOS ow patients was 0.9647 and cut-off value was 2.425 (85.11% sensitivity, 100% specificity), suggesting that ow people with serum miR-222-3p > 2.425 could basically be diagnosed with PCOS. miR-222-3p was positively-correlated with fasting plasma glucose (FPG), fasting insulin (FINS), homeostatic model assessment–insulin resistance (HOMA-IR), and low-density lipoprotein cholesterol (LDL-C) and negatively-correlated with high-density lipoprotein cholesterol (HDL-C). miR-222-3p was independently-correlated with diabetic and cardiovascular complications in PCOS (p < 0.05). High expression of miR-222-3p predicted high risks of diabetic and cardiovascular complications in PCOS. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α (r = − 0.2851, p = 0.0224; r = − 0.3151, p = 0.0310).ConclusionHigh expression of miR-222-3p assisted PCOS diagnosis and predicted increased risks of diabetic and cardiovascular complications. miR-222-3p targeted PGC-1α and was negatively-correlated with PGC-1α.

Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study

AimsPemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, was shown to ameliorate lipid abnormalities in a phase III clinical trial of patients with type 2 diabetes mellitus (T2DM). However, its efficacy has not been demonstrated in real-world clinical practice in patients with T2DM. MethodsWe performed a multi-center prospective observational study of the use of pemafibrate in patients with T2DM and hypertriglyceridemia versus conventional therapy, with or without a fibrate. The primary outcomes were the changes from baseline in fasting serum triglyceride (TG) and high-density lipoprotein-cholesterol (HDL-C) concentrations at week 52. ResultsWe recruited 650 patients, and data from 504 (252 per group) were analyzed after propensity score matching. In the pemafibrate group, both TG and HDL-C showed significant improvements (p < 0.001), and several indices reflecting TG-rich lipoproteins, low-density lipoprotein-cholesterol particle size, and liver enzyme elevations were significantly ameliorated compared with the control group, but there was no difference in glycemic control markers. One of the key secondary endpoints showed that switching from conventional fibrates to pemafibrate improved eGFR but increased uric acid concentration. ConclusionsIn patients with T2DM, pemafibrate has superior effects on lipid profile as well as liver and renal dysfunction to conventional fibrates.

Impact of dyslipidemia on the cumulative pregnancy outcomes after first ovarian stimulation.

ObjectivesTo investigate the cumulative live birth rate (CLBR) according to lipid metabolism in patients with or without polycystic ovarian syndrome (PCOS) undergoing their first complete in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles.PatientsA total of 1,470 patients with PCOS and 3,232 patients without PCOS who underwent their first complete IVF/ICSI cycles from January 2016 to June 2018 were included. During a minimum of 2 years of follow-up, they had achieved at least one live birth or used all available embryos. The cumulative pregnancy outcomes were compared based on the patients’ blood lipid parameters, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), in the two populations. Patients with an abnormal level of one or more of these four indicators were considered the dyslipidemia group. Patients whose four indicators were normal were considered the control group.ResultsAmong 1,470 patients with PCOS, the cumulative pregnancy outcomes were similar in the dyslipidemia group and control group. Logistic regression analysis showed that the TC levels were significantly negatively associated with the cumulative live birth rate (CLBR) after adjustment for confounding factors such as age and BMI (aOR 0.81, 95% CI 0.66-0.98, P<0.05). Among the 3,232 patients without PCOS, there was no significant difference in the cumulative pregnancy outcomes between the dyslipidemia group and the control group. No significant correlations were found in other logistic regression analyses.ConclusionsTC negatively impacts the CLBR after first ovarian stimulation in PCOS patients. PCOS patients with dyslipidemia caused by elevated TC may have a poor CLBR.

Sleep duration and lipid metabolism in patients with diabetes mellitus: from the POWER2DM study.

This study assesses the association between sleep duration and plasma lipid profiles in people with diabetes mellitus (DM). Sleep duration data were obtained in 91 patients from the POWER2DM study (NCT03588104). The patients were divided in tertiles, based on their sleep duration, and blood samples were obtained at the beginning and after 9months. Significant differences were found, specifically, patients in Tertile 3 (≥ 7.51h) showed lower plasma levels of high-density lipoprotein cholesterol HDL-c (p < 0.05), apolipoprotein A1 (apo-A1; p < 0.05) and low HDL-c/apo-A1 ratio (p < 0.05). This study shows that sleep duration is associated with plasma lipid profiles in people with DM.

Progression of carotid artery stenoses and target levels of lipid metabolism in patients following coronary artery bypass grafting

Background and Aims: To determine the progression of carotid artery stenosis (CAS) and assess its relationship with the achievement of target levels for lipid metabolism in patients following coronary artery bypass grafting (CABG) at the 5-year follow-up.

GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice

Dual agonists activating the peroxisome proliferator-activated receptors alpha and gamma (PPARɑ/ɣ) have beneficial effects on glucose and lipid metabolism in patients with type 2 diabetes, but their development was discontinued due to potential adverse effects. Here we report the design and preclinical evaluation of a molecule that covalently links the PPARɑ/ɣ dual-agonist tesaglitazar to a GLP-1 receptor agonist (GLP-1RA) to allow for GLP-1R-dependent cellular delivery of tesaglitazar. GLP-1RA/tesaglitazar does not differ from the pharmacokinetically matched GLP-1RA in GLP-1R signalling, but shows GLP-1R-dependent PPARɣ-retinoic acid receptor heterodimerization and enhanced improvements of body weight, food intake and glucose metabolism relative to the GLP-1RA or tesaglitazar alone in obese male mice. The conjugate fails to affect body weight and glucose metabolism in GLP-1R knockout mice and shows preserved effects in obese mice at subthreshold doses for the GLP-1RA and tesaglitazar. Liquid chromatography–mass spectrometry-based proteomics identified PPAR regulated proteins in the hypothalamus that are acutely upregulated by GLP-1RA/tesaglitazar. Our data show that GLP-1RA/tesaglitazar improves glucose control with superior efficacy to the GLP-1RA or tesaglitazar alone and suggest that this conjugate might hold therapeutic value to acutely treat hyperglycaemia and insulin resistance.

Altered Intestinal Microbiomes and Lipid Metabolism in Patients With Prolonged Disorders of Consciousness.

The intestinal microbiota regulate the brain function of the host through the production of a myriad of metabolites and are associated with various neurological diseases. Understanding the intestinal microbiome of patients with prolonged disorders of consciousness (DoC) is important for the evaluation and treatment of the disease. To investigate the differences in the intestinal microbiome and short-chain fatty acids (SCFAs) among patients in a vegetative state (VS), a minimally conscious state (MCS), and emerged from MCS (EMCS), as well as the influence of antibiotics on these patients, 16S ribosomal RNA (16S rRNA) sequencing and targeted lipidomics were performed on fecal samples from patients; in addition, analysis of the electroencephalogram (EEG) signals was performed to evaluate the brain function of these patients. The results showed that the intestinal microbiome of the three groups differed greatly, and some microbial communities showed a reduced production of SCFAs in VS patients compared to the other two groups. Moreover, reduced microbial communities and five major SCFAs, along with attenuated brain functional connectivity, were observed in MCS patients who were treated with antibiotics compared to those who did not receive antibiotic treatment, but not in the other pairwise comparisons. Finally, three genus-level microbiota—Faecailbacterium, Enterococcus, and Methanobrevibacter—were considered as potential biomarkers to distinguish MCS from VS patients, with high accuracy both in the discovery and validation cohorts. Together, our findings improved the understanding of patients with prolonged DoC from the intestinal microbiome perspective and provided a new reference for the exploration of therapeutic targets.

Differences in Muscle Strength, Physical Activity, and Cardiometabolic Risk Factors between Type 2 Diabetic Patients with and Without Benzodiazepines or Antipsychotic Medications

Abstract Objective: This study aimed to examine differences in muscle strength, physical activity, and cardiometabolic risk factors between Type 2 diabetic patients with and without benzodiazepines (BZD) or antipsychotic drugs (APD). Methods: The author conducted a cross-sectional study on patients with Type 2 diabetes (T2D) whose medication history was collected, and handgrip strength (HGS) was measured. Non-BZD- or APD-users were matched one-to-one with the BZD- or APD-users with respect to their age, gender, and body mass index. The differences in HGS, physical activity, and cardiometabolic risk factors such as blood pressure, lipid profile, and glycemic control between groups were assessed. Results: One hundred and ninety-six patients with and without BZD and 85 patients with and without APD were enrolled. HGS and walking time were significantly lower in patients treated with BZD or APD users than those without BZD or APD. Serum triglycerides levels were higher and high-density lipoprotein cholesterol levels were lower in patients treated with APD than those treated without APD. Both BZD and APD users had a longer sleep duration than nondrug users. Conclusion: BZD and APD were associated with decreased muscle strength and daily physical activity, and APD could impair lipid metabolism in patients with T2D, which may result in increasing the risk of cardiovascular (CV) events. BZDs and APDs should be judiciously prescribed for patients with T2D who are at high risk of CV disease.

Drug-Free Therapy of Lipid Metabolism in Patients with Cardiovascular Pathology, after COVID-19, in Course of Aftertreatment (Rehabilitation) in Sanatorium Conditions

COVID-19 has seen a rise in cardiovascular diseases (CVD). Treatment (rehabilitation) of COVID-19 survivors is one of the most difficult tasks, and non-drug correction of lipid metabolism in COVID-19 survivors is complicated by the low level of research on this issue. Aim. To conduct a comparative assessment of lipid metabolism and to estimate the efficacy of COVID-19 patients at the stages of rehabilitation in a sanatorium. Material and methods. The study enrolled 117 patients with CVD and after endovascular treatment (EV) who underwent COVID-19 for the last 6 months. Three groups for non-drug treatment with intranasal B1 electrophoresis and low-intensity infrared laser irradiation (LILI) were formed in patients with CVD who underwent COVID-19. Results and discussion. A significant increase in total cholesterol (TC) and triglycerides (TG) was found in 75.5% of patients after COVID-19, which was reflected in the electrocardiogram (ECG) in the form of right ventricular (RV) overstress. In addition to drug therapy, a combination of intranasal drug electrophoresis B1 and low-intensity infrared laser radiation (LILI) in pulsed mode (l=904 nm, power (PM) – 8-10 W/cm2, pulse duration 100-150 ns, frequency 80- 10000 Hz) on projection zones of the liver (angle of the 9th intercostal space in front/right and behind/right 5 minutes each) with special physical exercises can become as a method of additional lipid-correcting action. Lipidogram values in patients with IBI, HD and MI differ significantly, with the prevalence of total cholesterol levels, especially in patients with CAD and MI after a history of covid-infection, demonstrating the negative impact of viral infection on metabolic processes. Physiotherapeutic treatment in sanatoriums helped to eliminate lipid-vascular shifts – potential risks of thrombotic complications. Conclusion. Lipid metabolism correction in patients with CVD after COVID-19 allows reducing the risk of complications of the underlying disease and increasing the efficiency at the stage of recovery (rehabilitation) in a sanatorium.

Effect of non-surgical periodontal treatment on blood inflammatory parameters, glucose and lipid metabolism in patients with periodontitis and type 2 diabetes mellitus

Non-surgical periodontal treatment (NSPT) is the most essential part of periodontal treatment. Most patients with periodontitis and type 2 diabetes mellitus (T2DM) can achieve a satisfying outcome by NSPT. For these patients, NSPT can not only improve clinical periodontal parameters significantly and decrease the serum inflammatory status,but also improve glucose and lipid metabolism to some extent. Thus, NSPT is of great significance in preventing or retarding the progress of T2DM or even its complications. However, the special general condition of T2DM makes NSPT effects on periodontitis patients partially differ from those without systemic diseases. Therefore, the special characteristic led by T2DM should be taken into account in the decision and implementation of treatment plans for periodontitis patients. This paper will review the above issues mainly based on the studies of our research group.

Effect of traditional Chinese exercise on abnormal lipid metabolism in patients with atherosclerosis: a protocol for meta-analysis of randomised controlled trials

IntroductionAtherosclerosis (AS) is an abnormal response within the vessel wall to endothelial dysfunction and inflammatory cellular processes. Taijiquan exercise as a moderate-intensity aerobic exercise can control or reverse AS by...

Misleading clinical evidence and systematic reviews on ivermectin for COVID-19

<h3>Background:</h3> Avascular necrosis (AN) is a disabling disease affecting predominantly young men. It steadily progresses to secondary osteoarthritis. The rate of disability is high, because hip joint is most commonly...